STOCK TITAN

ANI Pharmaceuticals CEO Lalwani sells 4,082 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

ANI Pharmaceuticals Inc. President & CEO and director Nikhil Lalwani sold 1,318 shares on November 16, 2026 at a weighted-average price of $71.40 per share, and sold 4,082 shares on November 18, 2026 at a weighted-average price of $71.16 per share. The respective prices reflect multiple trades within ranges of $71.01–$71.55 and $71.00–$71.42. Both sales were made under a Rule 10b5-1 trading plan adopted May 26, 2026.

Insider Lalwani Nikhil
Role PRESIDENT & CEO
Sold 5,400 shs ($385K)
Share of Position Sold 1.6%
Type Security Shares Price Value
Sale Common Stock F1, F3 4,082 $71.16 $290K
Sale Common Stock F1, F2 1,318 $71.40 $94K
Holdings After Transaction: Common Stock — 328,289 shares (Direct)
Holdings Before and After: Common Stock, 333,689 to 328,289 shares (Direct)
Other Insiders: 2 other insiders reported open-market sales of this stock in the 30 days up to this filing.
Footnotes (3)
  1. F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 26, 2026.
  2. F2. The shares were sold in multiple trades at prices ranging from $71.01 to $71.55. The price reported above reflects the weighted average sales price.
  3. F3. The shares were sold in multiple trades at prices ranging from $71.00 to $71.42. The price reported above reflects the weighted average sales price.
Shares sold 1,318 shares November 16, 2026
Weighted-average sale price $71.40 per share November 16, 2026; multiple trades ranged from $71.01 to $71.55
Shares sold 4,082 shares November 18, 2026
Weighted-average sale price $71.16 per share November 18, 2026; multiple trades ranged from $71.00 to $71.42
Rule 10b5-1 trading plan regulatory
"Both sales were made under a Rule 10b5-1 trading plan adopted May 26, 2026"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ANIP shares did Nikhil Lalwani sell, and at what prices?

ANI Pharmaceuticals Inc. President & CEO Nikhil Lalwani sold 1,318 shares at $71.40 per share on November 16, 2026, and 4,082 shares at $71.16 per share on November 18, 2026; each reported price is a weighted average across multiple trades.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lalwani Nikhil

(Last)(First)(Middle)
C/O ANI PHARMACEUTICALS, INC.
104 CARNEGIE CENTER, SUITE 300

(Street)
PRINCETON NEW JERSEY 08540

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
PRESIDENT & CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/16/2026S(1)1,318D$71.4(2)332,371D
Common Stock11/18/2026S(1)4,082D$71.16(3)328,289D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 26, 2026.
2. The shares were sold in multiple trades at prices ranging from $71.01 to $71.55. The price reported above reflects the weighted average sales price.
3. The shares were sold in multiple trades at prices ranging from $71.00 to $71.42. The price reported above reflects the weighted average sales price.
Remarks:
/s/ Nikhil Lalwani, by attorney-in-fact Meredith W. Cook11/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading